Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: r-HuEPO
- First Posted Date
- 2016-05-10
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 61
- Registration Number
- NCT02767765
A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
Phase 3
Completed
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 503
- Registration Number
- NCT02763579
- Locations
- 🇺🇸
Florida Cancer Specialists - Fort Myers (Broadway), Fort Myers, Florida, United States
🇺🇸Comprehensive Cancer Centers of Nevada - Eastern Avenue, Las Vegas, Nevada, United States
🇺🇸Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States
A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT02761642
A Study to Determine Biopsy Rate in Participants With a First Relapse of Breast Cancer
Completed
- Conditions
- Breast Cancer
- Interventions
- Other: eBC treated participants
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 76
- Registration Number
- NCT02761616
- Locations
- 🇦🇷
Cemic; Oncologia Clinica, Buenos Aires, Argentina
🇦🇷Hospital de Morón, Moron, Argentina
🇦🇷CENICLAR, Rosario, Argentina
Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial (PERFECT)
Phase 3
Terminated
- Conditions
- HIV/HCV Coinfection
- Interventions
- Drug: Peginterferon Alfa-2
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 19
- Registration Number
- NCT02762383
A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 38
- Registration Number
- NCT02760797
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸University Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇫🇷Institut Gustave Roussy; Sitep, VILLEJUIF Cedex, France
Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus
Phase 4
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: Peg-Interferon Alpha-2ADrug: Ribavirin
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2016-08-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 180
- Registration Number
- NCT02761629
A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 225
- Registration Number
- NCT02748213
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 994
- Registration Number
- NCT02745119
- Locations
- 🇺🇸
Retina Group of Florida, Fort Lauderdale, Florida, United States
🇺🇸Maine Eye Center, Portland, Maine, United States
🇺🇸Vitreo-Retinal Associates, PC, Worcester, Massachusetts, United States
A Retrospective, Observational Registry of Participants With Avian Influenza Infection
Completed
- Conditions
- Influenza
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2016-04-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 648
- Registration Number
- NCT02743676
© Copyright 2025. All Rights Reserved by MedPath